Gedatolisib (Revtorpyk®) is a newly approved treatment for people with hormone receptor-positive, HER2-negative MBC without a PIK3CA mutation whose cancer has come back or who have completed at least one line of hormone therapy. Gedatolisib is a type of targeted therapy called a PAM pathway inhibitor (PAM = PI3K, AKT,and mTOR). A PAM pathway inhibitor is a drug that blocks a set of signals inside cancer cells that tells them to grow and survive, with the goal of slowing or stopping the cancer. Other PAM pathway inhibitors that are approved for MBC include alpelisib (Piqray®), inavolisib (Itovebi®), capivasertib (Truqap®), and everolimus (Afinitor®).
Click the links below to learn more about gedatolisib (Revtorpyk®) and other members of this class of targeted therapy drugs.
The PAM Pathway
- Susan G. Komen: PAM pathway inhibitors block growth signals in MBC
- Susan G. Komen: This graphic shows approved and experimental PAM pathway inhibitors for people with MBC
Gedatolisib (Revtorpyk®)
- Fred Hutch Cancer Center: Gedatolisib (Revtorpyk®) targets multiple proteins in the PAM pathway
- Cancer Today: Gedatolisib (Revtorpyk®) may increase progression-free survival whether or not the tumor has a mutation in PIK3CA
- Metastatic Trial Search: Trials for Inhibitors of PI3K, AKT, and mTOR
Last Modified on October 1, 2026